Business context and reporting period
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing precision-medicine treatments for central nervous system diseases. Its lead candidate, ANAVEX 2-73 (blarcamesine), is being studied for Alzheimer’s disease, Parkinson’s disease and Rett syndrome. The unaudited 10-Q covers the three and nine months ended June 30, 2023, the company’s fiscal third quarter. Anavex has not generated operating revenue.
Financial performance and position
| Metric | Three months ended June 30, 2023 | Nine months ended June 30, 2023 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $10.3 million | $33.7 million |
| General and administrative expense | $3.2 million | $9.4 million |
| Total operating expenses | $13.5 million | $43.1 million |
| Operating loss | $13.5 million | $43.1 million |
| Net loss | $11.3 million | $37.4 million |
| Basic and diluted loss per share | $0.14 | $0.47 |
| Net interest income | $1.8 million | $4.6 million |
Gross margin is not applicable because the company reported no revenue. Nine-month operating cash use was $21.9 million, versus $20.2 million in the prior-year period. Financing activities provided $27.6 million, primarily from common-stock sales under the Lincoln Park purchase agreement. Cash increased by $5.7 million to $154.8 million from September 30, 2022.
At June 30, 2023, total assets were $157.8 million, current liabilities were $11.1 million and working capital was $146.8 million. The balance sheet reports no debt. Common shares outstanding were 81.4 million at quarter-end, up from 77.9 million at September 30, 2022; 81.95 million were outstanding on August 8, 2023.
Material changes versus prior comparable periods
- Quarterly operating expenses rose 9% year over year; nine-month expenses rose 21%. Nine-month R&D expense increased by $7.1 million, reflecting higher personnel and stock-based compensation, manufacturing, trial-startup and Rett EXCELLENCE trial costs.
- Quarterly net loss narrowed to $11.3 million from $12.4 million, mainly because of higher interest income. Nine-month net loss increased to $37.4 million from $33.7 million, primarily due to higher R&D costs.
- Nine-month net other income increased to $5.8 million from $2.2 million, chiefly due to returns on invested cash, partly offset by a $1.0 million financing charge related to the 2023 purchase agreement.
- Cash used in operations increased to $21.9 million from $20.2 million. The company raised $26.7 million in gross proceeds by issuing 3.125 million shares under the Lincoln Park agreement; $123.3 million remained available under that agreement at June 30.
Outlook, commentary and risks
- Management expects operating cash flows to remain negative and R&D spending to increase as clinical programs advance. It says current working capital should meet requirements beyond 12 months after the financial statements’ issuance date; no specific cash-runway estimate is provided.
- Management reported that the Rett syndrome EXCELLENCE trial completed dosing in June 2023 and expected topline results in the second half of 2023. A pivotal six-month Parkinson’s disease study is planned; timing and regulatory pathway remain subject to further development and FDA guidance.
- The company highlighted positive topline results previously reported for its Alzheimer’s Phase 2b/3 trial and positive findings from earlier Rett and Parkinson’s studies. These are company-reported trial results; the filing does not establish regulatory approval or commercial efficacy.
- Material risks include clinical-trial safety and efficacy uncertainty, regulatory approval, development costs, reliance on third parties, intellectual-property challenges and the possibility of needing further financing. Anavex says it may delay or scale back R&D if financing is unavailable when needed.
- Australian research and development tax-incentive claims for 2019–2022 remain open to potential tax-authority review or audit. The company reported ordinary-course claims and litigation but did not expect pending matters to materially affect its financial statements. No material changes to previously disclosed risk factors were reported.
- The company has equity-issuance capacity under both the Lincoln Park purchase agreement and its at-the-market sales agreement, creating potential future dilution. No shares were sold under the at-the-market agreement during the nine-month period.
Most important facts for investors to verify
- Whether the anticipated EXCELLENCE Rett trial topline results were released in the stated second-half 2023 period, and what the complete results showed.
- The clinical and regulatory status, design, funding and timing of the planned pivotal Parkinson’s study and other announced programs.
- Cash burn, R&D commitments and whether management’s stated greater-than-12-month liquidity assessment remains valid as programs expand.
- Future share issuance under the Lincoln Park and at-the-market facilities, including resulting dilution and remaining availability.
- The outcome of any Australian tax-incentive review or audit, and any material developments in litigation or other contingencies.